Back to Journals » Drug Design, Development and Therapy » Volume 12

Synovial tissue quantitative proteomics analysis reveals paeoniflorin decreases LIFR and ASPN proteins in experimental rheumatoid arthritis

Authors Yang S, Xing ZH, Liu T, Zhou J, Liang QH, Tang T, Cui HJ, Peng WJ, Xiong XG, Wang Y

Received 12 October 2017

Accepted for publication 12 December 2017

Published 6 March 2018 Volume 2018:12 Pages 463—473


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Anastasios Lymperopoulos

Shu Yang,1 Zhihua Xing,1 Tao Liu,1 Jing Zhou,1 Qinghua Liang,1 Tao Tang,1 Hanjin Cui,1 Weijun Peng,2 Xingui Xiong,1 Yang Wang1

1Laboratory of Ethnopharmacology, Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Traditional Chinese Medicine, 2nd Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China

Background: Rheumatoid arthritis (RA) is a common worldwide public health problem, which causes a chronic, systemic inflammatory disorder of synovial joints. Paeoniflorin (PA) has achieved positive results to some extent for the treatment of RA.
Purpose: This study aimed to reveal the potential druggable targets of PA in an experimental RA model using quantitative proteomics analysis.
Study design and methods: Thirty Sprague-Dawley rats were randomly divided into a normal group, model group and PA group. PA (1 mg/kg) was used to treat collagen-induced arthritis (CIA) rats for 42 days. We used isobaric tags for relative and absolute quantitation-based quantitative proteomics to analyze the synovial tissue of rats. Ingenuity pathway analysis (IPA) software was applied to process the data. The proteins that were targeted via IPA software were verified by Western blots.
Results: We found that PA caused 86 differentially expressed proteins (≥1.2-fold or ≤0.84-fold) compared with the CIA group. Of these varied proteins, 20 significantly changed (p<0.05) proteins referred to 41 CIA-relative top pathways after IPA pathway analysis. Thirteen of the PA-regulated pathways were anchored, which intervened in 24 biological functions. Next, network analysis revealed that leukemia inhibitory factor receptor (LIFR) and asporin (ASPN), which participate in two significant networks, contributed the most to the efficacy of PA treatment. Additionally, Western blots confirmed the aforementioned druggable targets of PA for the treatment of RA.
Conclusion: The results reveal that PA may treat RA by decreasing two key proteins, LIFR and ASPN. Our research helps to identify potential agents for RA treatment.

Keywords: paeoniflorin, quantitative proteomic, ASPN, LIFR, rheumatoid arthritis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]